ZURA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zura Bio Limited (ZURA) for Potential Securities Fraud
NEW YORK CITY, NY / ACCESS Newswire / November 12, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Zura Bio Limited ("Zura Bio Limited") (NASDAQ:ZURA) concerning potential violations of the federal securities laws.
Zura Bio Limited shares fell a reported 68.2% in premarket trading after the Company reported that its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet its primary endpoint of percent change from baseline in total abscess and inflammatory nodule count at Week 16 at either dose tested. Key secondary endpoints were also missed, leading the Company to discontinue development of tibulizumab for hidradenitis suppurativa. As recently as October 27, 2026, the Company reported in a Form 8-K that "TibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026." On the same date, the Company filed a Form 10-Q reporting $3,913 in three-month and $13,302 in nine-month research and development spend for the program, as well as a Form S-3 registration statement asserting "we have not completed any clinical trials, and have no products approved for commercial sale." Additionally, between August 13 and August 18, 2026, Director Someit Sidhu filed Form 144 notices covering roughly 168,000 shares, selling 118,000 shares for approximately $658,083 in gross proceeds while representing no knowledge of undisclosed material adverse information. The investigation concerns whether Zura Bio Limited adequately disclosed the trial status and clinical results of tibulizumab ahead of discontinuing its hidradenitis suppurativa program.
If you purchased NASDAQ:ZURA securities and suffered a loss, contact the firm to review your shareholder rights or call at (212) 363-7500 to speak to our team.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP